StockNews.AI
NTLA
StockNews.AI
175 days

Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA

1. Class action lawsuit filed over alleged NTLA securities fraud. Losses traced to mid-2024 events. 2. Alleged misinformation on NTLA-3001 timeline undermined investor confidence. Program discontinuation followed reorganization. 3. NTLA announced major reorganization and 27% workforce reduction. Stock fell from $12.02 to $10.20.

5m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit and revealed discontinuation of NTLA-3001 signal management issues and reduced investor trust. Historically, biotech firms facing legal scrutiny, like J&J in past litigations, have experienced sharp price declines.

How important is it?

The lawsuit directly involves NTLA and resulted in a notable price drop, suggesting strong influence on investor sentiment and potential future impacts.

Why Short Term?

The immediate market reaction and pricing drop indicate short-term volatility as the lawsuit advances. Past cases have shown that legal actions can trigger near-term price adjustments until resolution.

Related Companies

CRSPEDIT
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=131765&wire=4 NTLA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants' statements included, among other things, confidence in the Company's timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain.   The truth emerged on January 9, 2025, when Intellia published a press release announcing Company reorganization. In pertinent part, defendants disclosed that Intellia would be halting all NTLA-3001 research and studies and that the Company would be reducing its workforce by 27% in 2025. Specifically, the Company announced that management decided to focus Intellia's resources on other pharmaceutical development and would be implementing cost saving in the form of a major reduction in force. As a result, defendants pipeline priority readjustment resulted in the Company's once-touted NTLA-3001's discontinuation.  Following this news, Intellia's stock price fell from a closing market price of $12.02 per share on January 8, 2025 to $10.20 per share on January 10, 2025. WHAT'S NEXT? If you suffered a loss in Intellia during the relevant time frame, you have until April 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected] Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News